This inventor holds 11 USPTO granted patents. Top assignee: Hoechst Aktiengesellschaft. Active years: 1988-1997.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1988-1997
Title: Hartmut Hanauske-Abel: Innovator in Pharmaceutical Chemistry
Introduction
Hartmut Hanauske-Abel is a distinguished inventor based in Dexheim, Germany. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 11 patents. His work primarily focuses on the development of innovative compounds that have potential therapeutic applications.
Latest Patents
Among his latest patents, Hanauske-Abel has developed pharmaceutical uses for pyridine-2,4- and -2,5-dicarboxylic acid amides. These inventions relate to derivatives of pyridine-2,4- and -2,5-dicarboxylic acid, which are designed to influence the metabolism of collagen and collagen-like substances. The compounds are also aimed at impacting the biosynthesis of Cl.q. His work in this area has the potential to lead to new medicaments that can significantly improve health outcomes.
Career Highlights
Hanauske-Abel has had a notable career at Hoechst Aktiengesellschaft, where he has been instrumental in advancing pharmaceutical research. His innovative approach and dedication to his work have earned him recognition in the scientific community. His patents reflect a commitment to developing effective treatments that address complex medical issues.
Collaborations
Throughout his career, Hanauske-Abel has collaborated with esteemed colleagues, including Volkmar Gunzler and Dietrich Brocks. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances the quality of research.
Conclusion
Hartmut Hanauske-Abel's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in medical treatments and therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
